Decibel Cannabis Company (DB) Q3 2024 earnings summary

Executive summary

• Net revenue reached $106M LTM, with a 52% CAGR since 2020, and adjusted EBITDA of $20M LTM, up 157% CAGR over the same period.

• Q3 2024 net revenue was $24.1M, up 9% sequentially but down 12% year-over-year due to competition and changes in international distribution.

• The acquisition of AgMedica accelerates international expansion, adding four new countries and increasing exportable flower capacity to 12.2 TPA GACP/EU GMP certified.

• Domestic operations remain stable and cash-flow positive, while international segments show double-digit sales growth in nascent markets.

• The company is led by an experienced executive team and board with a track record of capital efficiency and profitable growth.

Financial highlights

• 2025 pro forma expectations: net revenue of $130M, adjusted EBITDA of $25M, and adjusted free cash flow of $20M.

• LTM adjusted EBITDA margin at 19%, with gross margin among the highest in Canadian LPs at 36%.

• Gross margin before fair value adjustments improved to 53% in Q3 2024 from 44% in Q3 2023.

• AgMedica expected to contribute over $30M in revenue and $4M in adjusted EBITDA in 2025.

• 16 consecutive periods of positive EBITDA in the domestic segment, with 23% ROCE.

Outlook and guidance

• Expects to increase exports to 9 markets in 2025, up from 3 in 2024, leveraging AgMedica's platform.

• Management expects to remain in compliance with all financial covenants for the next twelve months.

• The company is shifting focus from Canadian domestic recreational sales to international markets, supported by AgMedica's EU-GMP-certified facility.

• Anticipates free cash flow contribution from AgMedica in 2025 with limited near-term working capital needs.